Detalhe da pesquisa
1.
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
J Endocrinol Invest
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696122
2.
Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study.
J Endocrinol Invest
; 43(4): 529-538, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31741320
3.
Growth hormone binding protein and growth hormone availability in acromegalic patients treated with long-acting octreotide (Sandostatin-LAR).
Eur J Endocrinol
; 136(1): 61-6, 1997 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-9037128
4.
Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment.
Eur J Endocrinol
; 143(3): 353-61, 2000 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-11022177
5.
Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Eur J Endocrinol
; 143(5): 577-84, 2000 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-11078980
6.
MicroRNA-552 in colorectal cancer with poor prognosis. Its role as a novel molecular biomarker.
Eur Rev Med Pharmacol Sci
; 22(5): 1171-1174, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29565469
7.
Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment.
Eur J Clin Pharmacol
; 36(3): 311-3, 1989.
Artigo
em Inglês
| MEDLINE | ID: mdl-2663524
8.
A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
Gynecol Endocrinol
; 5(3): 213-6, 1991 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-1776507
9.
Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin.
Int J Clin Pharmacol Ther Toxicol
; 29(8): 329-32, 1991 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-1743807
10.
Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
Clin Endocrinol (Oxf)
; 36(4): 369-74, 1992 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-1424170
11.
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?
J Endocrinol Invest
; 27(11): 1040-7, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15754736
12.
Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Endocrinol Exp
; 24(1-2): 175-85, 1990 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-2361459
13.
Gender- and age-related differences in the endocrine parameters of acromegaly.
J Endocrinol Invest
; 25(6): 532-8, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12109625
14.
Cholelithiasis and acromegaly: therapeutic strategies.
Clin Endocrinol (Oxf)
; 40(3): 401-6, 1994 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-8187305
15.
The effects of somatostatin analogs on tumor shrinkage in acromegaly.
J Endocrinol Invest
; 26(8 Suppl): 50-4, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-15233213